

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number  
WO 2004/029053 A1

(51) International Patent Classification<sup>7</sup>: C07D 471/08, A61K 31/55, A61P 25/00 // (C07D 471/08, 243:00, 221:00)

(21) International Application Number:  
PCT/DK2003/000639

(22) International Filing Date:  
29 September 2003 (29.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PA 2002 01456 30 September 2002 (30.09.2002) DK  
PA 2002 01738 11 November 2002 (11.11.2002) DK  
60/426,368 15 November 2002 (15.11.2002) US

(71) Applicant (for all designated States except US): NEUROSEARCH A/S [DK/DK]; 93 Pederstrupvej, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PETERS, Dan [SE/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). OLSEN, Gunnar, M. [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). NIELSEN, Elsebet, Østergaard [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). JØRGENSEN, Tino, Dyhring [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK). AHRING, Philip, K. [DK/DK]; c/o NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup (DK).

(74) Common Representative: NEUROSEARCH A/S; Att: Patent Department, 93 Pederstrupvej, DK-2750 Ballerup (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A1

(54) Title: NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE

WO 2004/029053



(I)

(57) Abstract: This invention relates to novel 1,4-diazabicycloalkane derivatives of formula (I): any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors

and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

## NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE

### TECHNICAL FIELD

5

This invention relates to novel 1,4-diazabicycloalkane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.

10 Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases 15 or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

### BACKGROUND ART

20 The endogenous cholinergic neurotransmitter, acetylcholine, exert its biological effect via two types of cholinergic receptors, the muscarinic Acetyl Choline Receptors (mAChR) and the nicotinic Acetyl Choline Receptors (nAChR).

As it is well established that muscarinic acetylcholine receptors dominate quantitatively over nicotinic acetylcholine receptors in the brain area important to 25 memory and cognition, and much research aimed at the development of agents for the treatment of memory related disorders have focused on the synthesis of muscarinic acetylcholine receptor modulators.

Recently, however, an interest in the development of nAChR modulators has emerged. Several diseases are associated with degeneration of the cholinergic 30 system i.e. senile dementia of the Alzheimer type, vascular dementia and cognitive impairment due to the organic brain damage disease related directly to alcoholism. Indeed several CNS disorders can be attributed to a cholinergic deficiency, a dopaminergic deficiency, an adrenergic deficiency or a serotonergic deficiency.

WO 00/34279 (Sanofi-Synthelabo) describes 1,4-diazabicyclo[3.2.2]nonane 35 derivatives having activity at the nicotinic receptors. Only six-membered heteroaryl derivatives are described. The five-membered heteroaryl derivatives of the present invention have not been described.

WO 01/55150 (Sanofi-Synthelabo) describes 1,4-diazabicyclo[3.2.2]nonane derivatives having activity at the nicotinic receptors. Only bicyclic heteroaryl derivatives

are described. The monocyclic heteroaryl derivatives of the present invention have not been described.

WO 01/92259 (Sanofi-Synthelabo) describes 1,4-diazabicyclo[3.2.2]nonane derivatives having activity at the nicotinic receptors. Only phenyl-isoxazole derivatives 5 are described. The thiadiazole derivatives of the present invention have not been described.

WO 01/92260 (Sanofi-Synthelabo) describes 1,4-diazabicyclo[3.2.2]nonane derivatives having activity at the nicotinic receptors. Only phenyl-thiazole derivatives are described. The thiadiazole derivatives of the present invention have not been 10 described.

EP 1219622 (Pfizer Ltd.) describes 1,4-diazabicyclo[3.2.2]nonane derivatives having activity at the nicotinic receptors. Only bicyclic heteroaryl derivatives are described. The monocyclic heteroaryl derivatives of the present invention have not been described.

15


## SUMMARY OF THE INVENTION

The present invention is devoted to the provision novel modulators of the nicotinic and/or of the monoamine receptors, which modulators are useful for the 20 treatment of diseases or disorders related to the cholinergic receptors, and in particular the nicotinic acetylcholine receptor (nAChR), the monoamine receptors 5-HTR, DAR and NER, and the biogenic amine transporters for 5-HT, DA and NE.

Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the 25 cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

30 The compounds of the invention may also be useful as diagnostic tools or monitoring agents in various diagnostic methods, and in particular for *in vivo* receptor imaging (neuroimaging), and they may be used in labelled or unlabelled form.

In its first aspect the invention provides novel 1,4-diazabicycloalkane derivatives of Formula I



any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein n is 1, 2 or 3;

X represents O, S or Se; and

5 Ar represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, 10 carbamoyl, amido, sulfamoyl, phenyl and benzyl.

In a second aspect the invention provides pharmaceutical compositions comprising a therapeutically effective amount of the 1,4-diazabicycloalkane derivative of the invention, an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically- 15 acceptable carrier or diluent.


Viewed from another aspect, the invention relates to the use of a 1,4-diazabicycloalkane derivative of the invention, or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, for manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder 20 or a condition which is responsive to modulation of cholinergic receptors and/or monoamine receptors.

In yet another aspect the invention provides a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease or disorder is responsive to modulation of 25 cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a 1,4-diazabicycloalkane derivative of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

30 Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.

#### DETAILED DISCLOSURE OF THE INVENTION

35 In its first aspect the present invention provides novel 1,4-diazabicycloalkane derivatives represented by the general Formula I




any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein  
n is 1, 2 or 3;

5 X represents O, S or Se; and

Ar represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, 10 cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl, phenyl and benzyl.

In a more preferred embodiment Ar represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group may optionally be substituted one or more times with substituents selected from the group 15 consisting of alkyl, alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub> and phenyl.


In a first preferred embodiment the compound of the invention is a 1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula II



20 wherein

X and Ar are as defined above.


In a more preferred embodiment the compound of the invention is a 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula III



25

wherein Ar is as defined above.

In another preferred embodiment the compound of the invention is a 4-oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula IV



wherein Ar is as defined above.

In a second preferred embodiment the carbocyclic aromatic (aryl) group is an optionally substituted phenyl, indenyl, naphthyl, azulenyl; fluorenyl, or anthracenyl 5 group.

In a more preferred embodiment the carbocyclic aromatic group is phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl, phenyl and benzyl.

10 In an even more preferred embodiment the carbocyclic aromatic group is phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, and phenyl.

In a most preferred embodiment the 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of the invention is

15 4-(5-Phenyl-1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;

or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof;

and the 4-oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of the invention is

20 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Phenyl-phenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

25 or

4-[5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

In a third preferred embodiment the heterocyclic aromatic (heteroaryl) group 30 is an optionally substituted aromatic monocyclic heterocyclic group, or an optionally substituted aromatic bi- or poly-heterocyclic heterocyclic group, which heterocyclic groups include benzo-fused 5- and 6-membered heterocyclic rings containing one or more heteroatoms, selected from nitrogen (N), oxygen (O), sulphur (S) and/or selen (Se).

In a more preferred embodiment the aromatic monocyclic heterocyclic group is an optionally substituted aromatic 5- or 6-membered heterocyclic monocyclic group.

In an even more preferred embodiment the optionally substituted aromatic monocyclic heterocyclic group is furanyl, in particular 2-furanyl or 3-furanyl; thienyl, in particular 2-thienyl or 3-thienyl; selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; pyrrolyl (azolyl), in particular 2-pyrrolyl or 3-pyrrolyl; oxazolyl, in particular oxazol-2-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl; imidazolyl, in particular 2-imidazolyl or 4-imidazolyl; pyrazolyl, in particular 3-pyrazolyl or 4-pyrazolyl; 10 isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; oxadiazolyl, in particular 1,2,3-oxadiazol-4- or 5-yl, or 1,3,4-oxadiazol-2-yl; triazolyl, in particular 1,2,3-triazol-4-yl or 1,2,4-triazol-3-yl; thiadiazolyl, in particular 1,2,3-thiadiazol-4- or 5-yl, or 1,3,4-thiadiazol-2-yl; pyridinyl, in particular 2-, 3- or 4-pyridinyl; pyridazinyl, in particular 3- or 4-pyridazinyl; pyrimidinyl, in particular 2-, 4- or 15 5-pyrimidinyl; pyrazinyl, in particular 2- or 3-pyrazinyl; and triazinyl, in particular 1,2,4- or 1,3,5-triazinyl.

In another preferred embodiment the compound of the invention is a 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of Formula III, wherein Ar represents an optionally substituted aromatic monocyclic heterocyclic group selected 20 from selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; imidazolyl, in particular 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; pyrazolyl, in particular 3-pyrazolyl, 4-pyrazolyl or 5-pyrazolyl; thiazolyl, in particular 2-thiazolyl or 5-thiazolyl; isothiazolyl, in particular 3-isothiazolyl, 4-isothiazolyl or 5-isothiazolyl; oxadiazolyl, in particular 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl or 1,3,4-oxadiazol-2-yl; furazanyl, in particular 3-furazanyl; triazolyl, in particular 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl or 25 1,2,4-triazol-5-yl; thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl or 1,2,4-thiadiazol-5-yl; pyridazinyl, in particular 3-pyridazinyl or 4-pyridazinyl; and triazinyl, in particular 1,3,5-triazin-2-yl.

In a more preferred embodiment the aromatic 5- or 6-membered heterocyclic monocyclic group is optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halogen,  $\text{CF}_3$ ,  $\text{CN}$ ,  $\text{NO}_2$ ,  $\text{NH}_2$  and phenyl.

In a most preferred embodiment the 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of the invention is

35 4-[5-(2-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
 4-[5-(3-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
 4-[5-(2-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
 4-[5-(4-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
 4-[5-(5-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-2-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-4-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(1-Methyl-5-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

10 4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-

15 diazabicyclo[3.2.2]nonane;

4-[5-(2-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

20 4-[5-(4-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-

25 diazabicyclo[3.2.2]nonane;

4-[1,3,4-Oxadizol-2-yl]-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Furazanyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

30 4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

35 4-[5-(1,2,4-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or

4-[5-(1,3,5-Triazin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

10 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

In yet another preferred embodiment the compound of the invention is a 4-oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of Formula IV, wherein Ar represents an optionally substituted aromatic monocyclic heterocyclic group selected from furyl, in particular 2-furyl or 3-furyl; pyridyl, in particular 2-pyridyl, 3-pyridyl or 4-pyridyl; thienyl, in particular 2-thienyl or 3-thienyl; pyrrolyl, in particular 2-pyrrolyl or 3-pyrrolyl; pyrimidinyl, in particular 2-pyrimidinyl, 4-pyrimidinyl or 5-pyrimidinyl; pyrazinyl; selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; oxazolyl, in particular 2-oxazolyl, 4-oxazolyl or 5-oxazolyl; isoxazolyl, in particular 3-isoxazolyl, 4-isoxazolyl or 5-isoxazolyl; imidazolyl, in particular 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; pyrazolyl, in particular 3-pyrazolyl, 4-pyrazolyl or 5-pyrazolyl; thiazolyl, in particular 2-thiazolyl, 4-thiazolyl or 5-thiazolyl; isothiazolyl, in particular 3-isothiazolyl, 4-isothiazolyl or 5-isothiazolyl; oxadiazolyl, in particular 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl or 1,3,4-oxadiazol-2-yl; furazanyl, in particular 3-furazanyl; triazolyl, in particular 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl or 1,2,4-triazol-5-yl; thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl or 1,2,4-thiadiazol-5-yl; pyridazinyl, in particular 3-pyridazinyl or 4-pyridazinyl; and triazinyl, in particular 1,3,5-triazin-2-yl.

In a most preferred embodiment the 4-oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of the invention is

30 4-[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

35 4-[5-(2-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-2-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-3-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(2-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(Pyrazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

10 4-[5-(3-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

15 4-[5-(3-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

20 4-[5-(4-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-2-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-4-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

25 4-[5-(1-Methyl-5-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

30 4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

35 4-[5-(2-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Iothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Iothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-

5 diazabicyclo[3.2.2]nonane;

4-[5-(1,3,4-Oxadizol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(3-Furazanyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,3-Triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

10 4-[5-(1,2,3-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

15 4-[5-(1,2,4-Triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-

20 diazabicyclo[3.2.2]nonane;

4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

25 4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or

4-[5-(1,3,5-Triazin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

30 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
acceptable addition salt thereof, or an N-oxide thereof.

In a fourth preferred embodiment the optionally substituted bicyclic aromatic heterocyclic group is indolyl, in particular 2-indolyl or 3-indolyl; isoindolyl, in particular 1-isoindolyl or 3-isoindolyl; benzo[b]furanyl, in particular 2-benzo[b]furanyl or 3-benzo[b]furanyl; benzo[b]thienyl, in particular 2-benzo[b]thienyl or 3-benzo[b]thienyl; benzoimidazolyl, in particular 2-benzoimidazolyl; benzothiazolyl, in particular 2-benzothiazolyl; quinolinyl, in particular 2-quinolinyl, 3-quinolinyl or 4-quinolinyl; isoquinolinyl, in particular 1-isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl; cinnolinyl, in particular 3-cinnolinyl or 4-cinnolinyl; phthalazinyl, in particular 1-phthalazinyl or 4-

phthalazinyl; quinazolinyl; in particular 2-quinazolinyl or 4-quinazolinyl; quinoxalinyl, in particular 2-quinoxalinyl or 3-quinoxalinyl.

In a more preferred embodiment the optionally substituted polycyclic aromatic heterocyclic group is a tricyclic heteroaryl group, in particular 2-acridinyl, 3-acridinyl, 6-acridinyl or 7-acridinyl; carbazolyl, in particular 2-carbazolyl, 3-carbazolyl, 6-carbazolyl or 7-carbazolyl; phenazinyl, in particular 2-phenazinyl, 3-phenazinyl, 7-phenazinyl or 8-phenazinyl; phenothiazinyl, in particular 2-phenothiazinyl, 3-phenothiazinyl, 7-phenothiazinyl or 8-phenothiazinyl; and phenoazinyl, in particular 2-phenoazinyl, 3-phenoazinyl, 7-phenoazinyl or 8-phenoazinyl.

10 In an even more preferred embodiment the compound of the invention is a 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of Formula III, wherein the polycyclic aromatic heterocyclic group is an optionally substituted bicyclic heteroaryl selected from quinolinyl, in particular 2-quinolinyl or 3-quinolinyl; isoquinolinyl, in particular 3-isoquinolinyl; cinnolinyl, in particular 3-cinnolinyl; indolizinyl, in particular 2-indolizinyl; benzimidazolyl, in particular 2-benzimidazolyl; benzothiazolyl, in particular 2-benzothiazolyl; phthalazinyl, in particular 7-phthalazinyl; quinazolinyl, in particular 2-quinazolinyl, quinoxalinyl, in particular 2-quinoxalinyl; naphthyridinyl, in particular 1,8-naphthyridin-2-yl or 1,8-naphthyridin-3-yl; and acridinyl, in particular 2-acridinyl or 3-acridinyl.

20 In a yet more preferred embodiment the bicyclic heteroaryl group is optionally substituted one or two times with substituents selected from the group consisting of alkyl, alkoxy, halogen,  $\text{CF}_3$ ,  $\text{CN}$ ,  $\text{NO}_2$ ,  $\text{NH}_2$ , and phenyl.

In a most preferred embodiment the 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of the invention is

25 4-[5-(2-Quinolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Quinolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Isoquinolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Cinnolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Indolizinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
30 4-[5-(1-Methyl-2-indoly)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

diazabicyclo[3.2.2]nonane;  
4-[5-(2-Benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
35 4-[5-(2-Benzothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(7-Phthalazinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Quinazolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Quinoxaliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(2-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or  
4-[5-(3-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
acceptable addition salt thereof, or an N-oxide thereof.

In yet another preferred embodiment the compound of the invention is a 4-  
10 oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative of Formula IV, wherein Ar  
represents an optionally substituted aromatic monocyclic heterocyclic group selected  
from benzothienyl, in particular 2-benzothienyl, 3-benzothienyl, 5-benzothienyl or 6-  
benzothienyl; benzofuryl, in particular 2-benzofuryl, 3-benzofuryl, 5-benzofuryl or 6-  
benzofuryl; quinolinyl, in particular 2-quinolinyl or 3-quinolinyl; isoquinolinyl, in  
15 particular 3-isoquinolinyl; cinnolinyl, in particular 3-cinnolinyl; indolizinyl, in particular 2-  
indolizinyl; indolyl, in particular 2-indolyl; benzimidazolyl, in particular 2-benzimidazolyl;  
benzothiazolyl, in particular 2-benzothiazolyl; phthalazinyl, in particular 7-phthalazinyl;  
quinazolinyl, in particular 2-quinazolinyl; quinoxaliny, in particular 2-quinoxaliny;  
naphthyridinyl, in particular 1,8-naphthyridin-2-yl or 1,8-naphthyridin-3-yl; acridinyl, in  
20 particular 2-acridinyl or 3-acridinyl; dibenzofuryl, in particular 2-dibenzofuryl, or 3-  
dibenzofuryl; dibenzothienyl, in particular 2-dibenzothienyl or 3-dibenzothienyl;  
phenoxazinyl, in particular 2-phenoxazinyl or 3-phenoxazinyl.

In a still more preferred embodiment the aromatic monocyclic heterocyclic  
group is optionally substituted one or two times with substituents selected from the  
25 group consisting of alkyl, alkoxy, halogen,  $\text{CF}_3$ ,  $\text{CN}$ ,  $\text{NO}_2$ ,  $\text{NH}_2$ , and phenyl.

In a most preferred embodiment the compound of the invention is

4-[5-(2-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

30 4-[5-(6-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(6-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

35 4-[5-(2-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Isoquinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Cinnolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Indolizinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Indolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-indolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(2-Benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
5 4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(2-Benzothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(7-Phtalazinoliny)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
10 4-[5-(2-Quinazolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Quinoxaliny)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
15 4-[5-(2-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
20 4-[5-(2-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Phenoazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
or  
25 4-[5-(3-Phenoazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
acceptable addition salt thereof, or an N-oxide thereof.

Any combination of two or more of the embodiments described herein is considered within the scope of the present invention.

#### Definition of Substituents

30 In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contain of from one to eighteen carbon atoms (C<sub>1-18</sub>-alkyl), more preferred of from one to six carbon atoms (C<sub>1-6</sub>-alkyl; lower alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a C<sub>1-4</sub>-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a C<sub>1-3</sub>-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.

In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C<sub>3-7</sub>-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

5 In the context of this invention a cycloalkyl-alkyl group designates a cycloalkyl group as defined above, which cycloalkyl group is substituted on an alkyl group as also defined above. Examples of preferred cycloalkyl-alkyl groups of the invention include cyclopropylmethyl and cyclopropylethyl.

10 In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to eight carbon atoms (C<sub>2-8</sub>-alkenyl), more preferred of from two to six carbon atoms (C<sub>2-6</sub>-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1- or 2-propenyl (allyl); 1-, 2- or 3-but enyl, or 1,3-butadienyl; 1-, 2-, 3-, 4- or 5-hexenyl, or 1,3-hexadienyl, or 1,3,5-15 hexatrienyl; 1-, 2-, 3-, 4-, 5-, 6-, or 7-octenyl, or 1,3-octadienyl, or 1,3,5-octatrienyl, or 1,3,5,7-octtetraenyl.

20 In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to eight carbon atoms (C<sub>2-8</sub>-alkynyl), more preferred of from two to six carbon atoms (C<sub>2-6</sub>-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl; 1-, or 2-propynyl; 1-, 2-, or 3-butynyl, or 1,3-butadiynyl; 1-, 2-, 3-, 4-pentynyl, or 1,3-pentadiynyl; 1-, 2-, 3-, 4-, or 5-hexynyl, or 1,3-hexadiynyl or 1,3,5-hexatriynyl; 1-, 2-, 3-, 4-, 5- or 6-heptynyl, or 1,3-heptadiynyl, or 25 1,3,5-hepttriynyl; 1-, 2-, 3-, 4-, 5-, 6- or 7-octynyl, or 1,3-octadiynyl, or 1,3,5-octtriynyl, or 1,3,5,7-octtetraynynyl.

30 In the context of this invention an alkoxy group designates an "alkyl-O-" group, wherein alkyl is as defined above. Examples of preferred alkoxy groups of the invention include methoxy and ethoxy.

35 In the context of this invention an alkoxy-alkyl group designates an "alkyl-O-alkyl" group, wherein alkyl is as defined above. Examples of preferred alkoxy-alkyl groups of the invention include methoxy-methyl, methoxy-ethyl, ethoxy-methyl, and ethoxy-ethyl.

40 In the context of this invention an alkoxy-alkoxy group designates an "alkyl-O-alkyl-O" group, wherein alkyl is as defined above. Examples of preferred alkoxy-alkoxy groups of the invention include methoxy-methoxy, methoxy-ethoxy, ethoxy-methoxy, and ethoxy-ethoxy.

45 In the context of this invention a cycloalkoxy group designates a "cycloalkyl-O" group, wherein cycloalkyl is as defined above.

In the context of this invention a cycloalkoxy-alkyl group designates a "cycloalkyl-O-alkyl" group, wherein cycloalkyl and alkyl are as defined above.

In the context of this invention a cycloalkoxy-alkoxy group designates a "cycloalkyl-O-alkyl-O-" group, wherein cycloalkyl and alkyl are as defined above.

5 In the context of this invention halogen represents a fluorine, a chlorine, a bromine or an iodine atom. Thus, a trihalogenmethyl group represents e.g. a trifluoromethyl group, a trichloromethyl group and similar trihalogen-substituted methyl groups.

10 In the context of this invention an acyl group designates a carboxy group (-COOH) or an alkyl-carbonyl group (alkyl-CO-), wherein alkyl is as defined above. Examples of preferred acyl groups of the invention include carboxy, acetyl, and propionyl.

#### Pharmaceutically Acceptable Salts

15 The 1,4-diazabicycloalkane derivative of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.

20 Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the sulphate derived from sulphuric acid, the formate derived from formic acid, the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulphonate derived from benzenesulphonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulphonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphthalene-2-sulphonic acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, 30 the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphonic acid, and the like. Such salts may be formed by procedures well known and described in the art.

Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a 1,4-diazabicycloalkane derivative of the invention and its pharmaceutically acceptable acid addition salt.

5 Metal salts of a 1,4-diazabicycloalkane derivative of the invention include alkali metal salts such as the sodium salt of a chemical compound of the invention containing a carboxy group.

In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" 10 include the alkyl-onium salts, in particular the methyl-onium salt, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.

### Steric Isomers

The 1,4-diazabicycloalkane derivative of the present invention may exist in 15 (+) and (-) forms as well as in racemic forms ( $\pm$ ). The racemates of these isomers and the individual isomers themselves are within the scope of the present invention.

Racemic forms can be resolved into the optical antipodes by known methods and techniques. One way of separating the diastereomeric salts is by use of an optically active acid, and liberating the optically active amine compound by 20 treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates, or camphorsulphonate) salts for example.

25 The 1,4-diazabicycloalkane derivative of the present invention may also be resolved by the formation of diastereomeric amides by reaction of the chemical compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the 30 chemical compound of the present invention with an optically active chloroformate or the like.

Additional methods for the resolving the optical isomers are known in the art. Such methods include those described by Jaques J, Collet A, & Wilen S in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

35 Optical active compounds can also be prepared from optical active starting materials.

### Methods of Preparation

The 1,4-diazabicycloalkane derivative of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present 5 application are known or may readily be prepared by conventional methods from commercially available chemicals.

Also one compound of the invention can be converted to another compound of the invention using conventional methods.

The end products of the reactions described herein may be isolated by 10 conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.

### Biological Activity

The present invention relates to novel 1,4-diazabicycloalkane derivatives 15 found to be cholinergic ligands at the nicotinic acetylcholine receptors (nAChR) and modulators of the monoamine receptors, in particular the biogenic amine transporters 5-HT, DA and NE. Moreover, preferred compounds of the invention show selective  $\alpha_7$  activity.

In the context of this invention the term "modulator" covers agonists, partial 20 agonists, antagonists and allosteric modulators of the receptor.

Due to their pharmacological profile the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of diseases or conditions as diverse as CNS related diseases, PNS related diseases, diseases related to smooth muscle contraction, endocrine disorders, diseases related to neuro-degeneration, diseases 25 related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

In a preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention are used for the treatment of diseases, disorders, or conditions relating to the central nervous system. Such diseases or disorders includes anxiety, cognitive 30 disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and 35 obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, peripheral neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

In another preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of diseases, disorders, or conditions associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.

In yet another preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of endocrine disorders, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

In still another preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.

In even another preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of inflammatory diseases, disorders, or conditions, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

In still another preferred embodiment the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

Finally the 1,4-diazabicycloalkane derivatives of the invention may be useful for the treatment of withdrawal symptoms caused by termination of use of addictive substances. Such addictive substances include nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol. Withdrawal from addictive substances is in general a traumatic experience characterised by anxiety and frustration, anger, anxiety, difficulties in concentrating, restlessness, decreased heart rate and increased appetite and weight gain.

In this context "treatment" covers treatment, prevention, prophylactics and alleviation of withdrawal symptoms and abstinence as well as treatment resulting in a voluntary diminished intake of the addictive substance.

In another aspect, the 1,4-diazabicycloalkane derivatives of the invention are used as diagnostic agents, e.g. for the identification and localisation of nicotinic receptors in various tissues.

### **Pharmaceutical Compositions**

In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the 1,4-diazabicycloalkane derivative of the invention.

While a 1,4-diazabicycloalkane derivative of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, 5 carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.

In a preferred embodiment, the invention provides pharmaceutical compositions comprising the 1,4-diazabicycloalkane derivative of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefore, and, optionally, other therapeutic 10 and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.

The pharmaceutical composition of the invention may be administered by any convenient route, which suits the desired therapy. Preferred routes of 15 administration include oral administration, in particular in tablet, in capsule, in dragé, in powder, or in liquid form, and parenteral administration, in particular cutaneous, subcutaneous, intramuscular, or intravenous injection. The pharmaceutical composition of the invention can be manufactured by any skilled person by use of standard methods and conventional techniques appropriate to the desired formulation. 20 When desired, compositions adapted to give sustained release of the active ingredient may be employed.

Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

25 The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing from about 0.1 to about 500 mg of active ingredient per 30 individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.

The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1  $\mu\text{g}/\text{kg}$  i.v. and 1  $\mu\text{g}/\text{kg}$  p.o. The upper limit of the dosage range is presently considered 35 to be about 10  $\text{mg}/\text{kg}$  i.v. and 100  $\text{mg}/\text{kg}$  p.o. Preferred ranges are from about 0.1  $\mu\text{g}/\text{kg}$  to about 10  $\text{mg}/\text{kg}/\text{day}$  i.v., and from about 1  $\mu\text{g}/\text{kg}$  to about 100  $\text{mg}/\text{kg}/\text{day}$  p.o.

### Methods of Therapy

The 1,4-diazabicycloalkane derivatives of the present invention are valuable nicotinic and monoamine receptor modulators, and therefore useful for the treatment of a range of ailments involving cholinergic dysfunction as well as a range of disorders 5 responsive to the action of nAChR modulators.

In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors, and which method 10 comprises administering to such a living animal body, including a human, in need thereof an effective amount of a 1,4-diazabicycloalkane derivative of the invention.

In a preferred embodiment, the disease, disorder or condition relates to the central nervous system.

In a preferred embodiment, the disease, disorder or condition is anxiety, 15 cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and 20 obesity, narcolepsy, nociception, AIDS-dementia, senile dementia, peripheral neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

25 In another preferred embodiment, the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.

In a third preferred embodiment, the disease, disorder or condition is 30 related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

In a fourth preferred embodiment, the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.

35 In a fifth preferred embodiment, the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

In a sixth preferred embodiment, the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

In a seventh preferred embodiment, the disease, disorder or condition is 5 associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.

It is at present contemplated that suitable dosage ranges are 0.1 to 1000 10 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.

15 A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.005 mg/kg i.v. and 0.01 mg/kg p.o. The upper limit of the dosage range is about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.001 to about 1 mg/kg i.v. and from about 0.1 to about 10 mg/kg p.o.

20

## EXAMPLES

The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.

25 **Example 1**

### Preparatory Example

All reactions involving air sensitive reagents or intermediates were performed under nitrogen and in anhydrous solvents. Magnesium sulfate was used as drying agent in the workup-procedures and solvents were evaporated under reduced 30 pressure.

1,4-Diazabicyclo[3.2.2]nonane (Intermediate compound) was prepared according to J. Med. Chem. 1993 36 2311-2320, and according to the following slightly modified method.

35 To the solution of 1,4-diazabicyclo[3.2.2]nonan-3-one (15.8 g, 113 mmol) in absolute dioxane (130 ml) LiAlH<sub>4</sub> (4.9 g, 130 mmol) was added under argon. The mixture was refluxed for 6 hours and then allowed to reach room temperature. Water (5 ml in 10 ml of dioxane) was added by drops to the reaction mixture, the mixture was stirred for 0.5 hour and then filtered off via glass filter. The solvent was evaporated

and the residue was distilled using Kugelrohr apparatus at 90°C (0.1 mbar) to yield 1,4-diazabicyclo[3.2.2]nonane (11.1 g, 78%) as colourless hygroscopic material.

1,4-Diazabicyclo[3.2.2]nonan-3-one (Intermediate compound)

5 To the solution of 3-quinuclidinone hydrochloride (45 g, 278 mmol) in 90 ml of water, hydroxylamine hydrochloride (21 g, 302 mmol) and sodium acetate ( $\text{CH}_3\text{COOHx3H}_2\text{O}$ , 83 g, 610 mmol) were added, the mixture was stirred at 70°C for 1 hour and then cooled to 0°C. The separated crystalline material was filtered off (without washing!) and dried *in vacuo* to yield 40.0 g of oxime.

10 The 3-quinuclidinone oxime (40.0 g) was added during 2 hours by small portions to polyphosphoric acid\* (190 g, prepared as described below\*), preheated to 120°C. The temperature of the solution during the reaction was kept at 130°C. After addition of all oxime the solution was stirred for 20 minutes at the same temperature, then transferred to an enamelled vessel and allowed to reach room temperature. The 15 acidic mixture was neutralized by a solution of potassium carbonate (500 g in 300 ml of water), transferred into 2000 ml flask, diluted with 300 ml of water and extracted with chloroform (3x600 ml). The combined organic extracts were dried with sodium sulphate, the solvent evaporated and the solid residue dried up *in vacuo* to yield 30.0 g (77%) of the mixture of lactams.

20 Crystallization of the obtained mixture from 1,4-dioxane (220 ml) gave 15.8 g (40.5%) of 1,4-diazabicyclo[3.2.2]nonan-3-one as colourless large crystals with mp 211-212°C.

The filtrate was evaporated and the residue was chromatographed on a silica gel (Merck, 9385, 230-400 mesh) column with acetone as eluent. The solvent 25 was evaporated and the residue recrystallized from ethyl etanoate to yield 1,3-diazabicyclo[3.2.2]nonan-4-one (10.2 g, 26%) as colourless fine crystals with mp 125-126°C.

Polyphosphoric acid\*

30 85% Orthophosphoric acid (500 g, 294 ml, 4.337 mol) was placed into 2000 ml flask and then phosphor pentoxide (750 g, 5.284 mol) was added at room temperature (ratio acid-pentoxide, 2:3). The mixture was stirred at 200-220°C for 2 hours to yield of 1250 g of polyphosphoric acid, containing 80% of  $\text{P}_2\text{O}_5$ .

35 2-Chloro-5-phenyl-1,3,4-thiadiazole (Intermediate compound)

2-Amino-5-phenyl-1,3,4-thiadiazole sulfate (25.12 g, 142 mmol) was stirred in concentrated hydrochloric acid (300 ml) at 0°C. Sodium nitrite (12.7 g, 184 mmol) was added during a period of 10 minutes. The reaction mixture was stirred at 50°C for 15 hours. The hydrochloric acid was evaporated. Aqueous sodium hydroxide (4 M,

250 ml) was added and the precipitate was filtered. Chromatography on silica gel with ethyl acetate as solvent gave a pure product. Yield 15.5 g (56%).

Method A

5 4-(5-Phenyl-1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound A1);

A mixture of 1,4-diazabicyclo[3.2.2]nonane (1.28 g, 10.2 mmol), 2-chloro-5-phenyl-1,3,4-thiadiazole (2.00 g, 10.2 mmol), triethylamine (2.83 ml, 20.3 mmol) and dioxane (20 ml) was stirred at reflux for 70 hours. Aqueous sodium hydroxide (1 M, 25 ml) was added and the mixture was extracted twice with ethyl acetate (2 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Yield 0.95 g, 23%. Mp 150.9°C.

15

The following compounds are prepared in a similar manner:

4-[5-(2-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A2);

4-[5-(3-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

20 (Compound A3);

4-[5-(2-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A4);

4-[5-(4-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A5);

25 4-[5-(5-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A6);

4-[5-(1-Methyl-2-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane (Compound A7);

4-[5-(1-Methyl-4-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-

30 diazabicyclo[3.2.2]nonane (Compound A8);

4-[5-(1-Methyl-5-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-

diazabicyclo[3.2.2]nonane (Compound A9);

4-[5-(3-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A10);

35 4-[5-(4-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A11);

4-[5-(5-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

(Compound A12);

4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A13);

4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A14);

5 4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A15);

4-[5-(2-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A16);

10 4-[5-(4-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A17);

4-[5-(5-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A18);

4-[5-(3-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A19);

15 4-[5-(4-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A20);

4-[5-(5-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A21);

4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A22);

20 4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A23);

4-[1,3,4-Oxadizol-2-yl]-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A24);

25 4-[5-(3-Furazanyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A25);

4-[5-(1,2,3-Triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A26);

4-[5-(1,2,3-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A27);

30 4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A28);

4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A29);

35 4-[5-(1,2,4-Triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A30);

4-[5-(1,2,4-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A31);

4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A32);

4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A33);

5 4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A34);

4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A35);

4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A36);

10 4-[5-(3-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A37);

4-[5-(4-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A38);

15 4-[5-(1,3,5-Triazin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A39);

4-[5-(2-Quinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A40);

4-[5-(3-Quinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

20 (Compound A41);

4-[5-(3-Isoquinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A42);

4-[5-(3-Cinnolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A43);

25 4-[5-(2-Indolizinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A44);

4-[5-(2-Indolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A45);

4-[5-(1-Methyl-2-indolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

30 (Compound A46);

4-[5-(2-Benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A47);

4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A48);

35 4-[5-(2-Benzothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A49);

4-[5-(7-Phtalazinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A50);

4-[5-(2-Quinazolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A51);

4-[5-(2-Quinoxaliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A52);

5 4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A53);

4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A54);

4-[5-(2-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane

10 (Compound A55); and

4-[5-(3-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound A56).

#### Method B

##### 15 2-Mercaptobenzyl-5-phenyl-1,3,4-oxadiazole (Intermediate compound)

Benzylbromide (16.8 ml, 141 mmol) was added over a time period of 10 minutes to a mixture of 5-phenyl-1,3,4-oxadiazole-2-thiol (commercially available) (25.2 g, 141 mmol), triethylamine (19.7 ml, 141 mmol) and ethanol (250 ml) at room temperature.

20 The mixture was allowed to stir at room temperature for 3 hours. Aqueous sodium hydroxide (1 M, 250 ml) was added and the mixture was extracted twice with dichloromethane (2 x 200 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title compound as an oil. Yield 34.2 g (90%).

25

#### Method C

##### 5-(2-Furyl)-1,3,4-oxadiazole-2-thiol (Intermediate compound)

Carbon disulphide (16.5 g, 216 mmol) was added to a mixture of 2-furoic hydrazide (13.6 g; 108 mmol), potassium hydroxide (6.68 g, 119 mmol) and methanol (125 ml). The mixture was allowed to stir at room temperature for 30 minutes followed by reflux for 8 hours. The methanol was evaporated. The aqueous phase was acidified to pH = 4 with concentrated hydrochloric acid. The product was isolated by filtration. Yield 12.9 g (72%).

#### 35 Method D

##### 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D1)

A mixture of 2-mercaptobenzyl-5-phenyl-1,3,4-oxadiazole (Method B) (1.0 g, 3.7 mmol), 1,4-diazabicyclo[3.2.2]nonane (0.47 g, 3.7 mmol) and

diisopropylethylamine (1.3 ml, 7.4 mmol) was stirred over for 4 days at 100°C. Aqueous sodium hydroxide (1 M, 25 ml) was added and the mixture was extracted twice with dichloromethane (2 x 20 ml). Chromatography on silica gel with dichloromethane, 10% methanol and 1% aqueous ammonia as solvent gave the title 5 compound as an oil. The corresponding salt was obtained by addition of a diethyl ether and methanol mixture (9:1) saturated with fumaric acid. Yield 0.47 g, 33%. Mp 176.6-178.8°C.

The following compounds are prepared in a similar manner:

10

4-[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D2)

Was prepared according to Method D. Mp 175°C.

15

4-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D3)

Was prepared according to Method D. Mp 190.1-191.2°C.

20

4-[5-(4-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D4)

Was prepared according to Method D. Mp 165.9-166.8°C.

25

4-[5-(2-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D5)

Was prepared according to Method D. Mp 161.8-162.7°C.

30

4-[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D6)

Was prepared according to Method D. Mp 176.8-177.5°C.

35

4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D7)

Was prepared according to Method D. Mp 184.3-185.8°C.

35

4-[5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D8)

Was prepared according to Method D. Mp 126-164°C.

4-[5-(4-Phenyl-phenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D9)

Was prepared according to Method D. Mp 238-239°C.

5 4-[5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane fumaric acid salt (Compound D10)

Was prepared according to Method D. Mp 194.6-195.7°C.

In analogy herewith the following compounds are prepared:

10 4-[5-(3-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D11);  
4-[5-(3-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D12);  
4-[5-(2-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D13);  
4-[5-(2-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D14);  
4-[5-(3-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D15);  
20 4-[5-(1-Methyl-2-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D16);  
4-[5-(1-Methyl-3-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D17);  
4-[5-(2-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D18);  
4-[5-(4-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D19);  
4-[5-(5-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D20);  
30 4-[5-(Pyrazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D21);  
4-[5-(2-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D22);  
4-[5-(3-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D23);  
4-[5-(2-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D24);  
4-[5-(4-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D25);

4-[5-(5-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D26);

4-[5-(3-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D27);

5 4-[5-(4-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D28);

4-[5-(5-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound 29);

4-[5-(2-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
10 (Compound D30);

4-[5-(4-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D31);

4-[5-(5-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D32);

15 4-[5-(1-Methyl-2-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane (Compound D33);

4-[5-(1-Methyl-4-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane (Compound D34);

4-[5-(1-Methyl-5-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
20 diazabicyclo[3.2.2]nonane (Compound D35);

4-[5-(3-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D36);

4-[5-(4-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D37);

25 4-[5-(5-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D38);

4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane (Compound D39);

4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
30 diazabicyclo[3.2.2]nonane (Compound D40);

4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane (Compound D41);

4-[5-(2-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D42);

35 4-[5-(4-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D43);

4-[5-(5-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
(Compound D44);

4-[5-(3-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D45);

4-[5-(4-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D46);

5 4-[5-(5-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D47);

4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D48);

4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D49);

10 4-[5-(1,3,4-Oxadizol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D50);

4-[5-(3-Furazanyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D51);

15 4-[5-(1,2,3-Triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D52);

4-[5-(1,2,3-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D53);

4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D54);

20 4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D55);

4-[5-(1,2,4-Triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D56);

25 4-[5-(1,2,4-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D57);

4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D58);

4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D59);

30 4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D60);

4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D61);

35 4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D62);

4-[5-(3-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D63);

4-[5-(4-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D64);

4-[5-(1,3,5-Triazin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D65);

5 4-[5-(2-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D66);

4-[5-(3-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D67);

4-[5-(5-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane 10 (Compound D68);

4-[5-(6-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D69);

4-[5-(2-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D70);

15 4-[5-(3-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D71);

4-[5-(5-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D72);

4-[5-(6-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane 20 (Compound D73);

4-[5-(2-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D74);

4-[5-(3-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D75);

25 4-[5-(3-Isoquinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D76);

4-[5-(3-Cinnolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D77);

4-[5-(2-Indolizinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane 30 (Compound D78);

4-[5-(2-Indolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D79);

4-[5-(1-Methyl-2-indolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D80);

35 4-[5-(2-Benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D81);

4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4- diazabicyclo[3.2.2]nonane (Compound D82);

4-[5-(2-Benzothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D83);

4-[5-(7-Phtalazinoliny)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D84);

5 4-[5-(2-Quinazolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D85);

4-[5-(2-Quinoxaliny)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D86);

4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
10 diazabicyclo[3.2.2]nonane (Compound D87);

4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane (Compound D88);

4-[5-(2-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D89);

15 4-[5-(3-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D90);

4-[5-(2-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D91);

4-[5-(3-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane  
20 (Compound D92);

4-[5-(2-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D93);

4-[5-(3-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D94);

25 4-[5-(2-Phenoxyazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D95); and

4-[5-(3-Phenoxyazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane (Compound D96).

### 30 Example 2

#### *In vitro* Inhibition of $^3\text{H}$ - $\alpha$ -Bungarotoxine Binding in Rat Brain

In this example the affinity of the compounds of the invention for binding to  $\alpha_7$ -subtype of nicotinic receptors is determined.

$\alpha$ -Bungarotoxine is a peptide isolated from the venom of the Elapidae snake *Bungarus multicinctus*. It has high affinity for neuronal and neuromuscular nicotinic receptors, where it acts as a potent antagonist.

$^3\text{H}$ - $\alpha$ -Bungarotoxine labels nicotinic acetylcholine receptors formed by the  $\alpha_7$  subunit isoform found in brain and the  $\alpha_1$  isoform in the neuromuscular junction.

### Tissue preparation

Preparations are performed at 0-4°C. Cerebral cortices from male Wistar rats (150-250 g) are homogenised for 10 seconds in 15 ml of 20 mM Hepes buffer containing 118 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO<sub>4</sub> and 2.5 mM CaCl<sub>2</sub> (pH 7.5) using an Ultra-Turrax homogeniser. The tissue suspension is subjected to centrifugation at 27,000 x g for 10 minutes. The supernatant is discarded and the pellet is washed twice by centrifugation at 27,000 x g for 10 minutes in 20 ml of fresh buffer, and the final pellet is then re-suspended in fresh buffer containing 0.01% BSA (35 ml per g of original tissue) and used for binding assays.

### Assay

Aliquots of 500 µl of homogenate are added to 25 µl of test solution and 25 µl of <sup>3</sup>H- $\alpha$ -bungarotoxin (2 nM, final concentration) and mixed and incubated for 2 hours at 37°C. Non-specific binding is determined using (-)-nicotine (1 mM, final concentration). After incubation, the samples are added 5 ml of ice-cold Hepes buffer containing 0.05% PEI and poured directly onto Whatman GF/C glass fibre filters (pre-soaked in 0.1% PEI for at least 6 hours) under suction, and immediately washed with 2 x 5 ml ice-cold buffer.

The amount of radioactivity on the filters is determined by conventional liquid scintillation counting. Specific binding is total binding minus non-specific binding.

The test value is given as an IC<sub>50</sub> (the concentration of the test substance which inhibits the specific binding of <sup>3</sup>H- $\alpha$ -bungarotoxin by 50%).

The results of these experiments are presented in Table 1 below.


Table 1

Inhibition of <sup>3</sup>H- $\alpha$ -Bungarotoxine Binding

Compound No.	IC <sub>50</sub> (µM)
Compound 1A	0.0067
Compound D1	0.0058
Compound D5	0.022

## CLAIMS

1. A 1,4-diazabicycloalkane derivative of Formula I:



5

any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof,  
wherein

n is 1, 2 or 3;

10 X represents O, S or Se; and

Ar represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, alkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido, sulfamoyl, phenyl and benzyl.


15

2. The compound of claim 1, wherein Ar represents a carbocyclic aromatic (aryl) group, or a heterocyclic aromatic (heteroaryl) group, which aromatic group may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, alkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub> and phenyl.

20

3. The compound of either one of claims 1-2, being a 1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula II

25




wherein

X and Ar are as defined in claim 1.


30 4. The compound of any one of claims 1-3, being a 4-thiadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula III

35



wherein Ar is as defined in claim 1.

5. The compound of any one of claims 1-3, being a 4-oxadiazolyl-1,4-diazabicyclo[3.2.2]nonane derivative represented by Formula IV



wherein Ar is as defined in claim 1.

10 6. The compound of any of claims 1-5, wherein the carbocyclic aromatic (aryl) group is an optionally substituted phenyl, indenyl, naphthyl, azulenyl, fluorenyl, or anthracenyl group.

15 7. The compound of claim 6, wherein the carbocyclic aromatic group is phenyl, optionally substituted one or two times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, alkoxy, cycloalkoxy, halogen, CF<sub>3</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, carboxy, carbamoyl, amido and sulfamoyl.

20 8. The compound of claim 4, which is  
4-(5-Phenyl-1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;  
or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

25 9. The compound of claim 5, which is  
4-(5-Phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Phenyl-phenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or  
30 4-[5-(2-Naphthyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
or an enantiomer or a mixture of enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

10. The compound of any one of claims 1-5, wherein the heterocyclic aromatic (heteroaryl) group is an optionally substituted aromatic monocyclic heterocyclic group, or an optionally substituted aromatic bi- or poly-heterocyclic heterocyclic group, which heterocyclic groups include benzo-fused 5- and 6-membered heterocyclic rings containing one or more heteroatoms, selected from nitrogen (N), oxygen (O), sulphur (S) and/or selen (Se).
11. The compound of claim 10, wherein the aromatic monocyclic heterocyclic group is an optionally substituted aromatic 5- or 6-membered heterocyclic monocyclic group.
12. The compound of claim 11, wherein the optionally substituted aromatic monocyclic heterocyclic group is furanyl, in particular 2-furanyl or 3-furanyl; thienyl, in particular 2-thienyl or 3-thienyl; selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; pyrrolyl (azolyl), in particular 2-pyrrolyl or 3-pyrrolyl; oxazolyl, in particular oxazol-2-, 4- or 5-yl; thiazolyl, in particular thiazol-2-, 4- or 5-yl; imidazolyl, in particular 2-imidazolyl or 4-imidazolyl; pyrazolyl, in particular 3-pyrazolyl or 4-pyrazolyl; isoxazolyl, in particular isoxazol-3-, 4- or 5-yl; isothiazolyl, in particular isothiazol-3-, 4- or 5-yl; oxadiazolyl, in particular 1,2,3-oxadiazol-4- or 5-yl, or 1,3,4-oxadiazol-2-yl; triazolyl, in particular 1,2,3-triazol-4-yl or 1,2,4-triazol-3-yl; thiadiazolyl, in particular 1,2,3-thiadiazol-4- or 5-yl, or 1,3,4-thiadiazol-2-yl; pyridinyl, in particular 2-pyridinyl, 3-pyridinyl or 4-pyridinyl; pyridazinyl, in particular 3-pyridazinyl or 4-pyridazinyl; pyrimidinyl, in particular 2-pyrimidinyl, 4-pyrimidinyl or 5-pyrimidinyl; pyrazinyl, in particular 2-pyrazinyl or 3-pyrazinyl; and triazinyl, in particular 1,2,4-triazinyl or 1,3,5-triazinyl.
13. The compound of claim 4, wherein Ar represents an optionally substituted aromatic monocyclic heterocyclic group selected from selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; imidazolyl, in particular 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; pyrazolyl, in particular 3-pyrazolyl, 4-pyrazolyl or 5-pyrazolyl; thiazolyl, in particular 2-thiazolyl or 5-thiazolyl; isothiazolyl, in particular 3-isothiazolyl, 4-isothiazolyl or 5-isothiazolyl; oxadiazolyl, in particular 1,2,3-oxadiazol-4-yl; 1,2,3-oxadiazol-5-yl or 1,3,4-oxadiazol-2-yl; furazanyl, in particular 3-furazanyl; triazolyl, in particular 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl or 1,2,4-triazol-5-yl; thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl or 1,2,4-thiadiazol-5-yl; pyridazinyl, in particular 3-pyridazinyl or 4-pyridazinyl; and triazinyl, in particular 1,3,5-triazin-2-yl.
14. The compound of claim 13, which is

4-[5-(2-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Selenophenyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
5 4-[5-(5-Imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-4-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-5-imidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
10 4-[5-(4-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
15 4-[5-(2-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Thiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
20 4-[5-(5-Isothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[1,3,4-Oxadizol-2-yl]-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Furazanyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
25 4-[5-(1,2,3-Triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-thiadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-  
30 diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
35 4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(4-Pyridazinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or 4-[5-(1,3,5-Triazin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
5 acceptable addition salt thereof, or an N-oxide thereof.

15. The compound of claim 5, wherein Ar represents an optionally substituted aromatic monocyclic heterocyclic group selected from furyl, in particular 2-furyl or 3-furyl; pyridyl, in particular 2-pyridyl, 3-pyridyl or 4-pyridyl; thienyl, in particular 2-thienyl or 3-thienyl; pyrrolyl, in particular 2-pyrrolyl or 3-pyrrolyl; pyrimidinyl, in particular 2-pyrimidinyl, 4-pyrimidinyl or 5-pyrimidinyl; pyrazinyl; selenophenyl, in particular 2-selenophenyl or 3-selenophenyl; oxazolyl, in particular 2-oxazolyl, 4-oxazolyl or 5-oxazolyl; isoxazolyl, in particular 3-isoxazolyl, 4-isoxazolyl or 5-isoxazolyl; imidazolyl, in particular 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; pyrazolyl, in particular 3-pyrazolyl, 4-pyrazolyl or 5-pyrazolyl; thiazolyl, in particular 2-thiazolyl, 4-thiazolyl or 5-thiazolyl; isothiazolyl, in particular 3-isothiazolyl, 4-isothiazolyl or 5-isothiazolyl; oxadiazolyl, in particular 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl or 1,3,4-oxadiazol-2-yl; furazanyl, in particular 3-furazanyl; triazolyl, in particular 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl or 1,2,4-triazol-5-yl; thiadiazolyl, in particular 1,3,4-thiadiazol-2-yl, 1,2,4-thiadiazol-3-yl or 1,2,4-thiadiazol-5-yl; pyridazinyl, in particular 3-pyridazinyl or 4-pyridazinyl; and triazinyl, in particular 1,3,5-triazin-2-yl.

16. The compound of claim 15, which is

25 4-[5-(2-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(3-Furyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(2-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(3-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(4-Pyridyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 30 4-[5-(2-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(3-Thienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(2-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(3-Pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(1-Methyl-2-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 35 4-[5-(1-Methyl-3-pyrrolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(2-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(4-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(5-Pyrimidinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; 4-[5-(Pyrazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Selenophenyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
5 4-[5-(5-Oxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Isoxazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
10 4-[5-(4-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-4-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-5-imidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
15 4-[5-(3-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-3-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-4-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
20 4-[5-(1-Methyl-5-pyrazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(4-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Thiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
25 4-[5-(4-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(5-Isothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Oxadizol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Oxadizol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,3,4-Oxadizol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
30 4-[5-(3-Furazanyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,3-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-1,2,3-triazol-4-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
35 4-[5-(1-Methyl-1,2,3-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-  
diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,2,4-Triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-1,2,4-triazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(1,3,4-Thiadiazol-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Thiadiazol-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,2,4-Thiadiazol-5-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(4-Pyridazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or

10 4-[5-(1,3,5-Triazin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
acceptable addition salt thereof, or an N-oxide thereof.

17. The compound of claim 10, wherein the optionally substituted bicyclic aromatic  
15 heterocyclic group is indolyl, in particular 2-indolyl or 3-indolyl; isoindolyl, in  
particular 1-isoindolyl or 3-isoindolyl; benzo[b]furanyl, in particular 2-  
benzo[b]furanyl or 3-benzo[b]furanyl; benzo[b]thienyl, in particular 2-  
benzo[b]thienyl or 3-benzo[b]thienyl; benzoimidazolyl, in particular 2-  
20 benzoimidazolyl; benzothiazolyl, in particular 2-benzothiazolyl; quinolinyl, in  
particular 2-quinolinyl, 3-quinolinyl or 4-quinolinyl; isoquinolinyl, in particular 1-  
isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl; cinnolinyl, in particular 3-cinnolinyl  
or 4-cinnolinyl; phthalazinyl, in particular 1-phthalazinyl or 4-phthalazinyl;  
quinazolinyl, in particular 2-quinazolinyl or 4-quinazolinyl; quinoxalinyl, in  
particular 2-quinoxalinyl or 3-quinoxalinyl.

25

18. The compound of claim 10, wherein the optionally substituted polycyclic aromatic  
heterocyclic group is a tricyclic heteroaryl groups, in particular 2-acridinyl, 3-  
acridinyl, 6-acridinyl or 7-acridinyl; carbazolyl, in particular 2-carbazolyl, 3-  
30 carbazolyl, 6-carbazolyl or 7-carbazolyl; phenazinyl, in particular 2-phenazinyl, 3-  
phenazinyl, 7-phenazinyl or 8-phenazinyl; phenothiazinyl, in particular 2-  
phenothiazinyl, 3-phenothiazinyl, 7-phenothiazinyl or 8-phenothiazinyl; and  
phenoazinyl, in particular 2-phenoazinyl, 3-phenoazinyl, 7-phenoazinyl or 8-  
phenoazinyl.

35 19. The compound of claim 4, wherein the polycyclic aromatic heterocyclic group is  
an optionally substituted bicyclic heteroaryl selected from quinolinyl, in particular  
2-quinolinyl or 3-quinolinyl; isoquinolinyl, in particular 3-isoquinolinyl; cinnolinyl, in  
particular 3-cinnolinyl; indolizinyl, in particular 2-indolizinyl; benzimidazolyl, in  
particular 2-benzimidazolyl; benzothiazolyl, in particular 2-benzothiazolyl;

phthalazinyl, in particular 7-phthalazinyl; quinazolinyl, in particular 2-quinazolinyl, quinoxaliny, in particular 2-quinoxaliny; naphthyridinyl, in particular 1,8-naphthyridin-2-yl or 1,8-naphthyridin-3-yl; and acridinyl, in particular 2-acridinyl or 3-acridinyl.

5

20. The compound of claim 19, which is

4-[5-(2-Quinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Quinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(3-Isoquinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
10 4-[5-(3-Cinnoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Indoliziny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-indolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-thiadiazol-2-yl]-1,4-  
15 diazabicyclo[3.2.2]nonane;  
4-[5-(2-Benzothiazolyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(7-Phtalazinoliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Quinazolinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Quinoxaliny)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
20 4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
4-[5-(2-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or  
4-[5-(3-Acridinyl)-1,3,4-thiadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;  
25 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-  
acceptable addition salt thereof, or an N-oxide thereof.

25

21. The compound of claim 5, wherein Ar represents an optionally substituted aromatic monocyclic heterocyclic group selected from benzothienyl, in particular 2-benzothienyl, 3-benzothienyl, 5-benzothienyl or 6-benzothienyl; benzofuryl, in particular 2-benzofuryl, 3-benzofuryl, 5-benzofuryl or 6-benzofuryl; quinoliny, in particular 2-quinoliny or 3-quinoliny; isoquinoliny, in particular 3-isoquinoliny; cinnoliny, in particular 3-cinnoliny; indoliziny, in particular 2-indoliziny; indolyl, in particular 2-indolyl; benzimidazolyl, in particular 2-benzimidazolyl; benzothiazolyl, in particular 2-benzothiazolyl; phthalazinyl, in particular 7-phthalazinyl; quinazolinyl, in particular 2-quinazolinyl; quinoxaliny, in particular 2-quinoxaliny; naphthyridinyl, in particular 1,8-naphthyridin-2-yl or 1,8-naphthyridin-3-yl; acridinyl, in particular 2-acridinyl or 3-acridinyl; dibenzofuryl, in particular 2-dibenzofuryl, or 3-dibenzofuryl; dibenzothienyl, in particular 2-dibenzothienyl or 3-dibenzothienyl; phenoxazinyl, in particular 2-phenoxazinyl or 3-phenoxazinyl.

22. The compound of claim 21, which is

4-[5-(2-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

5 4-[5-(5-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(6-Benzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(5-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

10 4-[5-(6-Benzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Quinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Isoquinolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Cinnolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

15 4-[5-(2-Indolizinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Indolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-2-indolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1-Methyl-2-benzimidazolyl)-1,3,4-oxadiazol-2-yl]-1,4-

20 diazabicyclo[3.2.2]nonane;

4-[5-(2-Benzothiazolyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(7-Phtalazinoliny)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Quinazolinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Quinoxalinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

25 4-[5-(1,8-Naphthyridin-2-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(1,8-Naphthyridin-3-yl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Acridinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

30 4-[5-(3-Dibenzofuryl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(3-Dibenzothienyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

4-[5-(2-Phenoxazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane; or

4-[5-(3-Phenoxazinyl)-1,3,4-oxadiazol-2-yl]-1,4-diazabicyclo[3.2.2]nonane;

35 or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.

23. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1-22, any of its enantiomers or any mixture of its

enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

24. Use of a compound of any of claims 1-22, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, for manufacture of a medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition which is responsive to modulation of cholinergic receptors and/or monoamine receptors.
- 10 25. The use according to claim 24, wherein the disease, disorder or condition relates to the central nervous system.
- 15 26. The use according to claim 24, wherein the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, 20 senile dementia, peripheral neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.
- 25 27. The use according to claim 24, wherein the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.
- 30 28. The use according to claim 24, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.
- 35 29. The use according to claim 24, wherein the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neuro-degeneration.

30. The use according to claim 24, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

5

31. The use according to claim 24, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, as well as pain caused by migraine, postoperative pain, and phantom limb pain.

10 32. The use according to claim 24, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and alcohol.

15

33. A method of the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease or disorder is responsive to modulation of cholinergic receptors and/or monoamine receptors, which method comprises the step of administering to such a living animal body, including a human, in need thereof a therapeutically effective amount of a compound of any of claims 1-22, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

20

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 00639

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C07D471/08 A61K31/55 A61P25/00 // (C07D471/08, 243:00,  
 221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 03 044020 A (SANOFI SYNTHELABO ; LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 30 May 2003 (2003-05-30) the whole document ---	1-33
A	US 5 478 939 A (TRYBULSKI EUGENE ET AL) 26 December 1995 (1995-12-26) claims ---	1-33
A	EP 0 307 140 A (MERCK SHARP & DOHME) 15 March 1989 (1989-03-15) the whole document ---	1-33
A	WO 01 92259 A (SANOFI SYNTHELABO ; LECLERC ODILE (FR); GALLI FREDERIC (FR); LOCHEA) 6 December 2001 (2001-12-06) the whole document ---	1-33
	-/-	

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 December 2003

13.01.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

GERD STRANDELL /EÖ

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/DK 05/00639

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 92260 A (SANOFI SYNTHELABO ;LECLERC ODILE (FR); GALLET THIERRY (FR); GALLI) 6 December 2001 (2001-12-06) the whole document ---	1-33
A	WO 00 34279 A (SANOFI SYNTHELABO ;JEUNESSE JEAN (FR); NEDELEC ALAIN (FR); EVEN LU) 15 June 2000 (2000-06-15) the whole document ---	1-33
A	WO 01 55150 A (SANOFI SYNTHELABO ;LECLERC ODILE (FR); NEDELEC ALAIN (FR); GALLI F) 2 August 2001 (2001-08-02) the whole document ---	1-33
A	EP 1 219 622 A (PFIZER PROD INC) 3 July 2002 (2002-07-03) the whole document -----	1-33

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/DK 03/00639

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: **33** because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.: **24, 33 all in part** because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Claims Nos.: 33

Claim 33 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions. These alleged effects must be well defined diseases or conditions.

-----

Continuation of Box I.2

Claims Nos.: 24, 33 all in part

The expressions "(a) disease or (a) disorder (or a condition which) is responsive to modulation of cholinergic receptors and/or monoamine receptors" in claims 24 and 33 may relate to a number of different disorders and conditions, which can not be clearly defined by these expressions. Thus, the search has mainly been restricted to the diseases mentioned in claims 25-32.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/DK 05/00639

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03044020	A	30-05-2003	FR WO	2832713 A1 03044020 A1		30-05-2003 30-05-2003
US 5478939	A	26-12-1995	NONE			
EP 0307140	A	15-03-1989	AT AU CA DE DE DK EP ES JP NZ PT ZA	102203 T 2206688 A 1338473 C 3888056 D1 3888056 T2 503388 A 0307140 A1 2061665 T3 1156979 A 226000 A 88423 A ,B 8806579 A		15-03-1994 16-03-1989 23-07-1996 07-04-1994 28-07-1994 27-04-1989 15-03-1989 16-12-1994 20-06-1989 25-06-1991 31-07-1989 26-07-1989.
WO 0192259	A	06-12-2001	FR AU EP WO HU US	2809731 A1 6404201 A 1289986 A1 0192259 A1 0302115 A2 2003114461 A1		07-12-2001 11-12-2001 12-03-2003 06-12-2001 28-10-2003 19-06-2003
WO 0192260	A	06-12-2001	FR AU EP WO HU	2809732 A1 6404301 A 1289987 A1 0192260 A1 0302157 A2		07-12-2001 11-12-2001 12-03-2003 06-12-2001 28-10-2003
WO 0034279	A	15-06-2000	FR AT AU DE EP WO JP US	2786770 A1 249460 T 1393000 A 69911241 D1 1135389 A1 0034279 A1 2002531565 T 6407095 B1		09-06-2000 15-09-2003 26-06-2000 16-10-2003 26-09-2001 15-06-2000 24-09-2002 18-06-2002
WO 0155150	A	02-08-2001	FR AT AU DE EP WO JP US	2804430 A1 247658 T 3559501 A 60100621 D1 1254139 A1 0155150 A1 2003523359 T 2003119840 A1		03-08-2001 15-09-2003 07-08-2001 25-09-2003 06-11-2002 02-08-2001 05-08-2003 26-06-2003
EP 1219622	A	03-07-2002	BR CA EP JP US US	0106462 A 2366268 A1 1219622 A2 2002255965 A 2002086871 A1 2003119837 A1		24-09-2002 29-06-2002 03-07-2002 11-09-2002 04-07-2002 26-06-2003